PROSECO: A study of the immune response to COVID-19 vaccination in people with lymphoma

This study does not involve any treatment. The researchers need blood samples from people with lymphoma before and after they have the
COVID-19 vaccine.


Purpose of study

The aim of this trial is to find out how well people with lymphoma respond to COVID-19 vaccination, and how long the immune response to the vaccine lasts.


What is involved

If you take part in this study, you carry on treatment or monitoring for your lymphoma as usual. You have the COVID-19 vaccination as recommended.

You have blood tests:

  • before you have your first dose of COVID-19 vaccine, if possible
  • 4 weeks after your first dose of COVID-19 vaccine, if possible
  • 2 to 4 weeks after your second dose of COVID-19 vaccine
  • 6 months after your second dose of COVID-19 vaccine
  • 12 months after your second dose of COVID-19 vaccine.

Scientists use these blood tests to measure your immune response to the vaccine. You will not find out the results of these blood tests.


Who can enter

Your consultant can give you advice on whether you might be suitable for this trial.

Around 680 people are needed for this trial.

You may be able to enter if:

  • You have lymphoma.
  • You have:
    - not had your COVID-19 vaccine yet
    - just had your first dose of COVID-19 vaccine
    - had your second dose of COVID-19 vaccine in the last 3 weeks.
  • You are 18 or over.

You won’t be able to enter if:

You have a serious illness that could affect your ability to take part in the trial.


Further information

More information about this trial is available at https://clinicaltrials.gov/ct2/show/NCT04858568